Lincoln National press release ( LNC ): Q4 Non-GAAP EPS of $2.21 beats by $0.31 . Revenue of $4.92B (-2.8% Y/Y) beats by $70M . More on Lincoln National Lincoln National: High Yield, Low Multiple, Overstated Risks Lincoln National: Continued Solid Performance Amidst Improvements Into 2026 Lincoln National Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on Lincoln National Historical earnings...
Lincoln National press release ( LNC ): Q4 Non-GAAP EPS of $2.21 beats by $0.31 . Revenue of $4.92B (-2.8% Y/Y) beats by $70M . More on Lincoln National Lincoln National: High Yield, Low Multiple, Overstated Risks Lincoln National: Continued Solid Performance Amidst Improvements Into 2026 Lincoln National Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on Lincoln National Historical earnings data for Lincoln National
Fortis press release ( FTS ): Q4 Non-GAAP EPS of C$0.90 beats by C$0.05 . More on Fortis Inc. Fortis: A New Capital Plan Extends Decades Of Dividend Growth Fortis Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on Fortis Inc. Historical earnings data for Fortis Inc. Dividend scorecard for Fortis Inc.
Fortis press release ( FTS ): Q4 Non-GAAP EPS of C$0.90 beats by C$0.05 . More on Fortis Inc. Fortis: A New Capital Plan Extends Decades Of Dividend Growth Fortis Q4 2025 Earnings Preview Seeking Alpha’s Quant Rating on Fortis Inc. Historical earnings data for Fortis Inc. Dividend scorecard for Fortis Inc.
GEO Group press release ( GEO ): Q4 GAAP EPS of $0.23 in-line. Revenue of $707.7M (+16.5% Y/Y) beats by $40.47M . we issued our initial financial guidance for 2026. We expect full year 2026 GAAP Net Income to be in a range of $0.99 to $1.07 per diluted share on annual revenues of $2.9 billion to $3.1 billion vs. $2.97B consensus and based on an effective tax rate of approximately 28 percent, inclu...
GEO Group press release ( GEO ): Q4 GAAP EPS of $0.23 in-line. Revenue of $707.7M (+16.5% Y/Y) beats by $40.47M . we issued our initial financial guidance for 2026. We expect full year 2026 GAAP Net Income to be in a range of $0.99 to $1.07 per diluted share on annual revenues of $2.9 billion to $3.1 billion vs. $2.97B consensus and based on an effective tax rate of approximately 28 percent, inclusive of known discrete items. We expect full year 2026 Adjusted EBITDA to be in a range of $490 million to $510 million. We expect total Capital Expenditures for the full year 2026 to be between $120 million and $155 million. For the first quarter 2026, we expect GAAP Net Income to be in a range of $0.17 to $0.19 per diluted share, on quarterly revenues of $680 million to $690 million $691.45M consensus. We expect first quarter 2026 Adjusted EBITDA to be between $107 million and $112 million. Shares +1.7% PM. More on GEO Group GEO Group Q4 2025 Earnings Preview GEO Group expands revolving credit facility by $100M Seeking Alpha’s Quant Rating on GEO Group Historical earnings data for GEO Group Financial information for GEO Group
West Pharmaceutical press release ( WST ): Q4 Non-GAAP EPS of $2.04 beats by $0.21 . Revenue of $805M (+7.5% Y/Y) beats by $10.2M . Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expecte...
West Pharmaceutical press release ( WST ): Q4 Non-GAAP EPS of $2.04 beats by $0.21 . Revenue of $805M (+7.5% Y/Y) beats by $10.2M . Full-year 2026 net sales are expected to be in a range of $3.215 billion to $3.275 billion, which assumes a mid-year 2026 close for the sale of SmartDose 3.5ml to AbbVie. Reported growth is expected to be between 4.6% and 6.5% while organic net sales growth is expected to be approximately 5% to 7%. Net sales guidance includes an estimated full-year 2026 benefit of 2 percentage points based on current foreign currency exchange rates. SmartDose® 3.5mL generated $55 million in revenues in the second half of 2025. These revenues are excluded to calculate our full-year 2026 organic revenue growth guidance. Full-year 2026 adjusted-diluted EPS is expected to be in a range of $7.85 to $8.20, representing growth of 7.7% to 12.5%. Full-year 2026 capital expenditures are expected to be in the range of $250 million to $275 million. First-quarter 2026 net sales are expected to be in the range of $770 million to $790 million, representing reported growth of 10.3% to 13.2% and organic growth of 4.6% to 7.4%. First-quarter adjusted-diluted EPS is expected to be in the range of $1.65 to $1.70, up 13.0% to 16.4%. More on West Pharmaceutical West Pharmaceutical Services, Inc. (WST) Discusses Integrated Prefillable Syringe Systems to Streamline Drug Development and Reduce Complexity Transcript West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript West Pharmaceutical Services, Inc. (WST) Presents at 44th Annual J.P. Morgan Healthcare Conference - Slideshow West Pharmaceutical Q4 2025 Earnings Preview Notable healthcare headlines for the week: J&J, Moderna, Bristol Myers in focus
PG&E press release ( PCG ): Q4 Non-GAAP EPS of $0.36 in-line. Tightening 2026 non-GAAP core EPS guidance to $1.64 to $1.66 per share versus $1.62 to $1.66 per share previously vs. $1.63 consensus. Amplifying the Simple Affordable Model, targeting customer bill inflation of 0-3% versus 2-4% previously. Reduced non-fuel operating and maintenance (O&M) costs in 2025 by 2.5%. Continued redeployment of...
PG&E press release ( PCG ): Q4 Non-GAAP EPS of $0.36 in-line. Tightening 2026 non-GAAP core EPS guidance to $1.64 to $1.66 per share versus $1.62 to $1.66 per share previously vs. $1.63 consensus. Amplifying the Simple Affordable Model, targeting customer bill inflation of 0-3% versus 2-4% previously. Reduced non-fuel operating and maintenance (O&M) costs in 2025 by 2.5%. Continued redeployment of O&M savings, bringing cumulative four-year total to over $700 million. Advanced 2 gigawatts (GW) of data center projects into final engineering since third quarter update, with approximately 3.6 GW now in final engineering. More on PG&E PG&E: An Undervalued Utility PG&E Corporation: Lackluster Yield Undermines The CapEx Plan And Data Center Pipeline PG&E Q4 2025 Earnings Preview PG&E reaches $100M shareholder settlement over 2017-18 California wildfires Seeking Alpha’s Quant Rating on PG&E
LXP Industrial Trust press release ( LXP ): Q4 FFO of $0.79 misses by $0.03 . Revenue of $86.74M (-14.0% Y/Y) beats by $0.69M . LXP estimates that its net income attributable to common shareholders for the year ended December 31, 2026 will be within an expected range of $(0.01) to $0.14 per diluted common share. LXP estimates its Adjusted Company FFO guidance for the year ending December 31, 2026,...
LXP Industrial Trust press release ( LXP ): Q4 FFO of $0.79 misses by $0.03 . Revenue of $86.74M (-14.0% Y/Y) beats by $0.69M . LXP estimates that its net income attributable to common shareholders for the year ended December 31, 2026 will be within an expected range of $(0.01) to $0.14 per diluted common share. LXP estimates its Adjusted Company FFO guidance for the year ending December 31, 2026, will be within an expected range of $3.22 to $3.37 per diluted common share. More on LXP Industrial Trust LXP Industrial Trust: Solid Fundamentals, But Better Risk-Adjusted Income From Preferred Seeking Alpha’s Quant Rating on LXP Industrial Trust Historical earnings data for LXP Industrial Trust Dividend scorecard for LXP Industrial Trust Financial information for LXP Industrial Trust